Cara Therapeutics is an emerging biotechnology company focused on developing novel therapeutics to treat human diseases associated with pain and inflammation. Cara possesses both near-term clinical development opportunities combined with proprietary approaches to developing first-in-class novel therapeutics. Cara's most advanced patented compound, CR845, is currently undergoing clinical testing for acute pain and pruritis. This best-in-class compound possesses unique analgesic and anti-inflammatory activities appropriate for multiple therapeutic applications. In addition, Cara aims to develop a future pipeline of first-in-class molecules at novel analgesic and anti-inflammatory targets using its proprietary drug screening technology.

Sichuan Haisco Pharmaceutical Co., Ltd., established on 2003-09-29, Business scope includes licensed projects:pharmaceutical production;Drug import and export;Pharmaceutical commissioned production;Drug retail(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments,The specific business items are subject to the approval documents or licenses of relevant departments)General project:Medical Research and Experimental Development;Specialty Chemicals Sales(Free of Hazardous Chemicals);Import and export;Technology Import and Export;Technical Services,technology development,technical consulting,Technology Exchange,technology transfer,Technology Promotion(Except for projects subject to approval by law,Carry out business activities independently in accordance with the law with a business license).

Haisco Pharmaceutical Group Co., Ltd. engages in the research, development, manufacture, and sale of pharmaceutical products and medical equipment. Its products include active pharmaceutical ingredients and generic drugs. The company offers the drugs for anesthesia & analgesia, diabetes mellitus & complications, tumor, neuralgia, parenteral nutrition, cardio-cerebrovascular, digestive and respiratory diseases. Haisco Pharmaceutical Group was founded in 2000 and is headquartered in Shannan, China.

Liaoning Haisco Pharmaceutical Co., Ltd., established on 2005-05-19, Business scope includes production:Freeze-dried powder injection,Freeze-dried powder injection(hormones),small volume injection,powder injection(Cephalosporins),large volume injection,large volume injection(Multi-layer co-extrusion infusion bag),API[methylprednisolone succinate(hormones),arginine glutamate,Cinepazide Maleate),Sterile API(Cefmenoxime hydrochloride,Cefotiam Hydrochloride).Chemical materials(Excluding hazardous chemicals and controlled chemicals);Import and transfer of medical technology;R&D and production of formula food for special medical purposes;Import and export of goods and technology.Corporate Image Planning Service;Business Management Consulting Services;Production of pharmaceutical packaging materials.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments.)

Lek Pharmaceuticals dd, a subsidiary of Novartis AG, is a company headquartered in Ljubljana, Slovenia, that develops, manufactures and markets drugs and pharmaceutical products. Robert Ljoljo is the CEO, in this role since 2019. On November 21, 2002 Novartis AG acquired Lek Pharmaceuticals dd for $689.24 million.

Arizona Board of Regents oversees college activities. The company was founded in 1864 and is headquartered in Phoenix, AZ.

Degussa AG is the world's third largest producer of precious metals. The company operates three divisions; precious metals and banking, which is involved in precious metals trading, production of precious metals and the manufacture of precious metal compounds and products in addition to operating its own bank, 'Degussa Bank', which is a universal bank providing traditional banking services. Chemical products is the second division and is involved in manufacturing fine and special chemicals, rubbers, pigments and chemical catalysts. The third and final division, health and nutrition is involved in manufacturing pharmaceuticals, dental chemicals and fodder additives. The company has subsidiaries in Germany, other European countries, USA, Brazil, Singapore, Japan and South Korea.

Ciba-Geigy AG was manufacturing pharmaceuticals. The company was merged with Sandoz Ltd. to create Novartis AG. The company was founded in 1884 and was headquartered in Basle, Switzerland.

Hoechst AG produced specialty chemicals and pharmaceutical products. It products ranged in areas of heart cycle, thrombose, central nervous system, onkologie, diabetes, metabolic illnesses, internal medicine and vaccines. Founded in 1863, the company was headquartered in Frankfurt am Main, Germany.

Celltech Co., Ltd. is engaged in producing and developing healthcare and biopharmaceutical products. Its main products include anticancer cell therapy which is named by NKM(Natural Killer Mix cell) Injection, GMP(Good Manufacturing Practice) system and medical devices. The company was founded on August 20, 1986 and is headquartered in Sungnam, South Korea.

ExSAR has offered drug discovery services to pharmaceutical, biotechnology and academic laboratories since its founding in 1997. In 2005, ExSAR initiated a program of collaborative research relationships to discover new therapeutics for the treatment of protein misfolding disorders. The aim is to become the leading drug developer in a rapidly growing $10+ billion market in metabolic and neurodegenerative disorders.\nMany of these disorders are characterized by mutations which lead to protein misfolding and instability followed subsequently by protein degradation. Many of these diseases currently lack any effective treatment. ExSAR is now a clinical developmental stage company dedicated to identifying, developing and commercializing small-molecule therapeutics for diseases of protein conformation. ExSAR expects to initiate clinical studies for the treatment of Tay Sachs, Sandhoff and Gaucher Diseases.

Prosidion Ltd. manufactures products for treatment of metabolic diseases such as diabetes and obesity. The company's products include oral inhibitors of dipeptidyl peptidase, glycogen phosphorylase inhibitor and glucokinase activator. It was founded in 2003 and is headquartered in Oxford, UK

Zywie believe in the power of connection. They are building a healthcare ecology where every individual is connected. Where there is seamless collaboration between healthcare professionals, institutions and patients. Where there is a meaningful flow of information to enable the best decision making in real time. Where there is informed care each step of the way. They are offering you consistent and predictable healthcare.

Tiandi Hengyi Pharmaceutical Co., Ltd., established on 2006-08-02, The scope of business includes chemical preparations,Chemical raw materials,Manufacture of Chemical Products;Chinese herbal extract,Production of Chinese patent medicines;medicine,Biological product,Research and development of chemical products;Chinese herbal medicine processing;Sales of pharmaceutical raw materials;medical information,Technical Advisory Services;Technology intermediary service;Import and export of goods or technology(Except for the import and export of goods and technologies that are prohibited by the state or involve administrative approval).(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)

Sanofi is a global healthcare company. Among their duties are researching disease causes, determining starting points for drug treatment, developing drugs, producing active ingredients, and delivering finished drugs and active ingredients. Specialists in vaccines, rare diseases, rare blood disorders, neurology, immunology, oncology, diabetes, cardiovascular diseases, and consumer healthcare.

Ajinomoto Co. is a global manufacturer of high-quality seasonings, processed foods, beverages, amino acids, pharmaceuticals and specialty chemicals. For many decades Ajinomoto Co. has contributed to food culture and human health through wide-ranging application of amino acid technologies. Today, the company is becoming increasingly involved with solutions for improved food resources, human health and global sustainability. Founded in 1909 and now operating in 26 countries, Ajinomoto Co. had net sales of JPY 1,197.3 billion (USD 15.1 billion) in fiscal 2011. The Ajinomoto Group Standards of Business Conduct (hereinafter the "Standards of Conduct") describe the conduct that every member of the Ajinomoto Group must understand and practice every day in order to implement the Ajinomoto Group Philosophy in accordance with the Ajinomoto Group Way. The Standards of Conduct also represent the commitments made to all stakeholders by Ajinomoto Group companies. Ajinomoto aim to be "a group of companies that contributes to human health globally" by continually creating unique value to benefit customers. To become a global group of food companies centered on the world's No. 1 seasoning business. To become a global group of aminoscience companies that contributes to humankind with the world's No. 1 amino acid technology. To become a group of health-promoting companies with a scientific approach to good taste and health.

Novartis AG is a holding company, which engages in the development, manufacture, and marketing of healthcare products. It operates through the following segments: Innovative Medicines, Sandoz, and Corporate. The Innovative Medicines segment researches, develops, manufactures, distributes and sells patented pharmaceuticals, and is composed of two business units: Novartis Oncology and Novartis Pharmaceuticals. The Sandoz segment develops, manufactures and markets finished dosage form medicines as well as intermediary products, including active pharmaceutical ingredients. The Corporate segment refers to group management and central services. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.

Elro Pharma engages in pharmaceutical research and development activities.